|Bid||10.59 x 800|
|Ask||10.70 x 1000|
|Day's Range||10.41 - 10.69|
|52 Week Range||7.13 - 15.24|
|Beta (5Y Monthly)||0.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 07, 2023 - Feb 13, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||35.33|
We can readily understand why investors are attracted to unprofitable companies. For example, although...
The FDA rejects Eli Lilly's (LLY) seeking accelerated approval of a new Alzheimer's drug, donanemab, due to the limited number of patients with at least 12 months of drug exposure data.
Novavax stands out with its more traditional, protein-based COVID-19 vaccine; MannKind is making a name for itself with inhaled therapies for diabetics and patients with lung disorders; and Anavex has a promising Alzheimer's therapy.